Plempel M
J Antimicrob Chemother. 1984 May;13(5):447-63. doi: 10.1093/jac/13.5.447.
The triazole derivative BAY N 7133 has been tested for its antimycotic efficacy on oral administration in vivo and compared with ketoconazole in mice infected with Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans and in guinea pig trichophytosis. On starting administration at the same time as infection and using daily doses between 25 and 100 mg/kg, the agent protected the mice in all experimental models, even mouse aspergillosis for which ketoconazole was not adequately effective. BAY N 7133 was also effective for mouse candidosis by parenteral administration and was effective for guinea pig trichophytosis on topical application.
已对三唑衍生物BAY N 7133进行了体内口服抗真菌功效测试,并在感染白色念珠菌、烟曲霉和新型隐球菌的小鼠以及豚鼠皮肤癣菌病模型中与酮康唑进行了比较。在感染同时开始给药,每日剂量为25至100mg/kg时,该药物在所有实验模型中均能保护小鼠,甚至对酮康唑效果不佳的小鼠曲霉菌病也有效。BAY N 7133通过肠胃外给药对小鼠念珠菌病也有效,局部应用对豚鼠皮肤癣菌病也有效。